Shots: The sBLA is based on P-II KEYNOTE-158 study assessing Keytruda (200mg, q3w) in patients with solid tumors. The study also supported Merck’s 2017 FDA approval for Keytruda as the first cancer treatment based on a biomarker, regardless of cancer type, in MSI-H or dMMR solid tumors The application seeks accelerated approval of Keytruda as […]Read More
Shots: ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) The focus of the collaboration is to develop innovative cancer therapies, highlighting the potential of Freenome’s platform providing tumor and immune signatures for hematological […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
